5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.

By M. Mack, M. Leon, Craig R. Smith, D. C. Miller, J. Moses, E. Tuzcu, J. Webb, P. Douglas, W. Anderson, Eugene H. Blackstone and 15 more. The Lancet, 2015

1,499 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f2da5f9f6542ee62b1f3cb059ac1643fa1885b9d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “ies and multicenter registries that include large numbers of high-risk patients of Aortic Transcatheter Valve) IA trial of a balloon-expandable valve (50,53), th at 30 days, 1 year, 2 years, and 5 years (p1⁄40.”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “ies and multicenter registries that include large numbers of high-risk patients of Aortic Transcatheter Valve) IA trial of a balloon-expandable valve (50,53), th at 30 days, 1 year, 2 years, and 5 years (p1⁄40.”